Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma.

K Abou-Alfa, Ghassan; Meyer, Tim; Cheng, Ann-Lii; B El-Khoueiry, Anthony; Rimassa, Lorenza; Ryoo, Baek-Yeol; Cicin, Irfan; Merle, Philippe; Chen, YenHsun; Park, Joong-Won; Blanc, Jean-Frederic; Bolondi, Luigi; Klümpen, Heinz-Josef; L Chan, Stephen; Zagonel, Vittorina; Pressiani, Tiziana; Ryu, Min-Hee; P Venook, Alan; Hessel, Colin; E Borgman-Hagey, Anne; Schwab, Gisela; K Kelley, Robin

doi:10.1056/nejmoa1717002

Public

Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma.

Published in The New England journal of medicine • Jul 5, 2018

NobleIDark:/48914/w1/20260526/222D5214Record on NobleID

Authors:

Ghassan K Abou-Alfa

,

Tim Meyer

,

Ann-Lii Cheng

Abstract

BACKGROUND: Cabozantinib inhibits tyrosine kinases, including vascular endothelial growth factor receptors 1, 2, and 3, MET, and AXL, which are implicated in the progression of hepatocellular carcinoma and the development of resistance to sorafenib, the standard initial treatment for advanced diseas...

Discussions